Yasushi Goto
Overview
Explore the profile of Yasushi Goto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
187
Citations
2512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torasawa M, Yoshida T, Shiraishi K, Yagishita S, Ono H, Uehara Y, et al.
Lung Cancer
. 2025 Mar;
202:108494.
PMID: 40088580
Background: In EGFR-mutated lung adenocarcinoma (EGFRm LUAD), EGFR mutations do not necessarily result in increased EGFR expression (EGFR-exp), which differs among patients. However, the factors influencing EGFR-exp and the impact...
2.
Shukuya T, Asao T, Goto Y, Mimori T, Takayama K, Kaira K, et al.
Lancet Oncol
. 2025 Mar;
26(3):331-342.
PMID: 40049197
Background: Despite the poor prognosis of advanced or recurrent thymic carcinoma, the rarity of thymic carcinoma has delayed the development and introduction of novel pharmacotherapy options. Carboplatin plus paclitaxel remains...
3.
Wu Y, Kim H, Soo R, Zhou Q, Akamatsu H, Chang G, et al.
J Thorac Oncol
. 2025 Mar;
PMID: 40024442
Introduction: Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, showed significantly longer progression-free survival (PFS) than crizotinib in the phase 3 CROWN trial (NCT03052608) in patients with previously untreated advanced...
4.
Satoh H, Okuma Y, Shinno Y, Masuda K, Matsumoto Y, Yoshida T, et al.
Lung Cancer
. 2025 Feb;
202:108453.
PMID: 40020466
Background: Advancements in pharmacotherapy, including molecular targeted therapies and immune checkpoint inhibitors, have revolutionized the treatment for Stage IV non-small cell lung cancer (NSCLC) over the past two decades. However,...
5.
Miyauchi E, Nishio M, Ohashi K, Osoegawa A, Kikuchi E, Kimura H, et al.
JTO Clin Res Rep
. 2025 Feb;
6(3):100783.
PMID: 39990134
Introduction: On the basis of the IMpower133 trial, atezolizumab plus carboplatin and etoposide (CE) is approved as first-line treatment for extensive-stage (ES)-SCLC. The J-TAIL-2 study evaluated atezolizumab plus CE in...
6.
Takeuchi T, Horinouchi H, Takasawa K, Mukai M, Masuda K, Shinno Y, et al.
BMC Med Inform Decis Mak
. 2025 Feb;
25(1):85.
PMID: 39962486
Background: The clinical information housed within unstructured electronic health records (EHRs) has the potential to promote cancer research. The National Cancer Center Hospital (NCCH) is widely recognized as a leading...
7.
Fujii H, Okuma Y, Hirata M, Shinno Y, Yoshida T, Goto Y, et al.
JTO Clin Res Rep
. 2025 Feb;
6(2):100691.
PMID: 39906181
Comprehensive genomic profiling (CGP) has progressed rapidly and plays an important role in advancing precision medicine in oncology. However, CGP provides opportunities for molecular-targeted therapy, but it also unveils incidental...
8.
Miyamoto R, Goto Y, Fujito T, Abe H, Kunugiza Y
Radiol Case Rep
. 2025 Feb;
20(4):1900-1903.
PMID: 39897751
Total knee replacement with mega prosthesis for periprosthetic fractures after total knee arthroplasty is related to early functional recovery, but aseptic loosening of the implant has been a major reoperation...
9.
Qi Z, Tokuhiro S, Odegaard J, Wienke S, Karnoub M, Feng W, et al.
J Mol Diagn
. 2025 Jan;
27(2):119-129.
PMID: 39880580
This study demonstrates the analytical and clinical validity of the approved (United States and Japan) plasma-based Guardant360 companion diagnostic (CDx) test for selecting patients with human epidermal growth factor receptor...
10.
Masuda K, Yoshida T, Motoi N, Shinno Y, Matsumoto Y, Okuma Y, et al.
Thorac Cancer
. 2025 Jan;
16(1):e15529.
PMID: 39809728
Background: Schlafen 11 (SLFN-11) has been identified as a sensitizer of tumor cells to DNA-damaging agents. However, the relationship between SLFN-11 expression and clinical outcomes in patients with small cell...